Venetoclax is the first BCL-2 inhibitor approved for the treatment of patients with CLL, in combination with a BTK inhibitor or a CD20-targeting monoclonal antibody [11,12,13]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.